Lupin rises on getting USFDA nod to market Rufinamide oral suspension

Lupin Limited, one of the leading multinational pharmaceutical companies announced on Monday post the trading session that it has received approval from United States Food & Drug Administration (USFDA) to market Rufinamide oral suspension.  

Rufinamide oral suspension 40 mg/ml is a generic equivalent of Banzel oral suspension of Eisai Inc, which is used in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients of age one year and older.   

According to IQVIA MAT, September 2020 data had estimated annual sales of USD 124.5 million in the US.  

Lupin develops and commercialises branded & generic formulations, biotechnology products as well as APIs in more than 100 markets in the US, South Africa, and across the Asia Pacific (APAC), Latin America, Europe, & Middle-East regions. It commands a leadership position in the cardiovascular, anti-diabetic, and respiratory segments. On the revenue front, it earns around 38 per cent from the domestic market, 37 per cent from the USA, 1 per cent from Japan and 24 per cent from other markets.  

The stock of Lupin closed at Rs 930.30, up by 4.31 per cent on Monday. It recorded an intraday high of Rs 991.8 and an intraday low of Rs 875. However, at 10.01 am on Tuesday, it is trading at Rs 932.20, up by 0.20 per cent on BSE.